{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:38Z","timestamp":1792039598776,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"publisher","award":["215905"],"award-info":[{"award-number":["215905"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109606","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:02:01Z","timestamp":1788390121000},"page":"109606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4899-0472","authenticated-orcid":false,"given":"Rafael","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1181-921X","authenticated-orcid":false,"given":"Tarje","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Killingberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Fritzke","family":"Emdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7236-7536","authenticated-orcid":false,"given":"Vibeke Grotnes","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-1534","authenticated-orcid":false,"given":"Bj\u00f8rn Henning","family":"Gr\u00f8nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8142-7441","authenticated-orcid":false,"given":"P\u00e5l","family":"S\u00e6trom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7563","key":"10.1016\/j.lungcan.2026.109606_b0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109606_b0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-024-01953-9","article-title":"Small cells - big issues: biological implications and preclinical advancements in small cell lung cancer","volume":"23","author":"Solta","year":"2024","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.lungcan.2026.109606_b0015","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109606_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109606_b0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109606_b0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109606_b0035","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/his.14872","article-title":"Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma","volume":"82","author":"Handa","year":"2023","journal-title":"Histopathology"},{"issue":"13\u201314","key":"10.1016\/j.lungcan.2026.109606_b0040","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gad.314815.118","article-title":"POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer","volume":"32","author":"Huang","year":"2018","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109606_b0045","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s13577-022-00669-6","article-title":"The role of YAP1 in small cell lung cancer","volume":"35","author":"Saito","year":"2022","journal-title":"Hum. Cell"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109606_b0050","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109606_b0055","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-23-2360","article-title":"Molecular and pathologic characterization of YAP1-expressing small cell lung cancer cell lines leads to reclassification as SMARCA4-deficient malignancies","volume":"30","author":"Ng","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109606_b0060","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/path.5922","article-title":"Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study","volume":"257","author":"Megyesfalvi","year":"2022","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109606_b0065","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2026.109606_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105062","article-title":"Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer","volume":"102","author":"Park","year":"2024","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109606_b0075","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jtho.2023.05.008","article-title":"Clinical benefit from immunotherapy in patients with SCLC Is associated with tumor capacity for antigen presentation","volume":"18","author":"Rudin","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109606_b0080","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3390\/jcm13113120","article-title":"Landscape and treatment options of shapeshifting small cell lung cancer","volume":"13","author":"Gu","year":"2024","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109606_b0085","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","article-title":"Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade","volume":"42","author":"Nabet","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109606_b0090","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s12890-024-03221-4","article-title":"Characteristics of molecular subtypes and cinical outcomes in the immunotherapy Queue of extensive-stage small cell lung cancer patients","volume":"24","author":"Li","year":"2024","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109606_b0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12943-024-02014-x","article-title":"Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study","volume":"23","author":"Xie","year":"2024","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109606_b0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"JCO."},{"issue":"23","key":"10.1016\/j.lungcan.2026.109606_b0105","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109606_b0110","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1158\/1078-0432.CCR-23-1689","article-title":"Durvalumab \u00b1 tremelimumab + platinum-etoposide in extensive-stage small cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden","volume":"30","author":"Paz-Ares","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109606_b0115","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2025.04.007","article-title":"High-dose versus standard-dose twice-daily thoracic radiotherapy in limited-stage SCLC: final survival data, long-term toxicity, and relapse patterns in a randomized, open-label, phase II trial","volume":"20","author":"Gr\u00f8nberg","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109606_b0120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jtho.2021.08.763","article-title":"Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers","volume":"17","author":"Qu","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109606_b0125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12957-022-02528-y","article-title":"Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)","volume":"20","author":"Ding","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.lungcan.2026.109606_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108033","article-title":"The molecular subtypes of small cell lung cancer defined by key transcription factors and their clinical significance","volume":"198","author":"Yu","year":"2024","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109606_b0135","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lungcan.2026.109606_b0140","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12950-015-0058-3","article-title":"Portrait of inflammatory response to ionizing radiation treatment","volume":"12","author":"Di Maggio","year":"2015","journal-title":"J. Inflamm. (Lond.)"},{"key":"10.1016\/j.lungcan.2026.109606_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109606_b0150","doi-asserted-by":"crossref","first-page":"10347","DOI":"10.1038\/s41598-024-61145-9","article-title":"Clinical significance of the advanced lung cancer inflammation index in patients with limited-stage small cell lung cancer treated with chemoradiotherapy","volume":"14","author":"Seo","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2026.109606_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115067","article-title":"The tumor immune microenvironment of SCLC is not associated with its molecular subtypes","volume":"212","author":"Velut","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109606_b0160","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","article-title":"Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer","volume":"39","author":"Chan","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109606_b0165","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41416-022-02103-y","article-title":"Molecular features and evolutionary trajectory of ASCL1+ and NEUROD1+ SCLC cells","volume":"128","author":"Zhang","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109606_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107183","article-title":"Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy","volume":"179","author":"Shirasawa","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109606_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.779276","article-title":"Prognostic implications of molecular subtypes in primary small cell lung cancer and their correlation with cancer immunity","volume":"12","author":"Qi","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109606_b0180","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jtho.2020.11.006","article-title":"YAP1 expression in SCLC defines a distinct subtype with t-cell-inflamed phenotype","volume":"16","author":"Owonikoko","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109606_b0185","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109606_b0190","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jtho.2025.07.022","article-title":"REST represses neuroendocrine transcriptional programs and enables antitumor immunity in SCLC","volume":"20","author":"Fatherree","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109606_b0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41421-024-00703-x","article-title":"Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer","volume":"10","author":"Jin","year":"2024","journal-title":"Cell Discov."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109606_b0200","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ctm2.620","article-title":"Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer","volume":"11","author":"Chen","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109606_b0205","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/jcp-2023-209109","article-title":"Molecular subtypes, predictive markers and prognosis in small-cell lung carcinoma","volume":"78","author":"Zhu","year":"2025","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109606_b0210","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s40001-026-04052-1","article-title":"Heterogeneous associations between molecular subtypes of small cell lung cancer and survival prognosis: a systematic review highlighting knowledge gaps","volume":"31","author":"Li","year":"2026","journal-title":"Eur. J. Med. Res."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109606_b0215","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jb\/mvt032","article-title":"EMT and EndMT: regulated in similar ways?","volume":"153","author":"Saito","year":"2013","journal-title":"J. Biochem."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109606_b0220","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/9511","article-title":"Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo","volume":"5","author":"Sethi","year":"1999","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109606_b0225","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","article-title":"Overcoming chemotherapy resistance in SCLC","volume":"16","author":"Herzog","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109606_b0230","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s43018-024-00839-5","article-title":"Two distinct epithelial-to-mesenchymal transition programs control invasion and inflammation in segregated tumor cell populations","volume":"5","author":"Youssef","year":"2024","journal-title":"Nat Cancer."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109606_b0235","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/1878-0261.12083","article-title":"EMT and MET: necessary or permissive for metastasis?","volume":"11","author":"Jolly","year":"2017","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109606_b0240","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/1078-0432.CCR-15-0876","article-title":"A patient-derived, pan-cancer EMT Signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition","volume":"22","author":"Mak","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109606_b0245","doi-asserted-by":"crossref","unstructured":"Gronberg BH, Aanerud M, Dumoulin DW, et al. Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC). J Clin Oncol. 2025;43(17_suppl):LBA8005-LBA8005. doi:10.1200\/JCO.2025.43.17_suppl.LBA8005.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8005"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:07:58Z","timestamp":1792037278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":49,"alternative-id":["S0169500226006677"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109606","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109606"}}